ChiCTR2100047103 版本V1.2 版本创建时间2021/12/27 22:47:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100047103 

最近更新日期:

Date of Last Refreshed on:

2021-12-27 17:58:02 

注册时间:

Date of Registration:

2021-06-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

虚弱对妇科癌症患者术后恢复质量的影响

Public title:

the effect of frailty on postoperative recovery quality of gynecological cancer paients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

虚弱对妇科癌症患者术后恢复质量的影响

Scientific title:

the effect of frailty on postoperative recovery quality of gynecological cancer paients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘春梅 

研究负责人:

魏昕 

Applicant:

Liu Chunmei 

Study leader:

Wei Xin 

申请注册联系人电话:

Applicant telephone:

+86 17754159750

研究负责人电话:

Study leader's telephone:

+86 13956975101

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2219739797@qq.com

研究负责人电子邮件:

Study leader's E-mail:

kekaiyuan6282@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市庐阳区庐江路17号

研究负责人通讯地址:

安徽省合肥市庐阳区庐江路17号

Applicant address:

17 Lujiang Road, Luyang District, Hefei, Anhui

Study leader's address:

17 Lujiang Road, Luyang District, Hefei, Anhui

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国科学技术大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of University of Science and Technology of China

研究负责人所在单位:

中国科学技术大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of University of Science and Technology of China

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021KY伦理第094号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中国科学技术大学附属第一医院(安徽省立医院)医学研究伦理委员会

Name of the ethic committee:

Medical Research Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

伦理委员会批准日期:

Date of approved by ethic committee:

2021-05-18 00:00:00

伦理委员会联系人:

胡怡然

Contact Name of the ethic committee:

Hu Yiran

伦理委员会联系地址:

安徽省合肥市庐阳区庐江路17号

Contact Address of the ethic committee:

17 Lujiang Road, Luyang District, Hefei, Anhui

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 62282931

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国科学技术大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of University of Science and Technology of China

研究实施负责(组长)单位地址:

安徽省合肥市庐阳区庐江路17号

Primary sponsor's address:

17 Lujiang Road, Luyang District, Hefei, Anhui

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

中国科学技术大学附属第一医院

具体地址:

庐阳区庐江路17号

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Address:

17 Lujiang Road, Luyang District

经费或物资来源:

经费由研究者筹集

Source(s) of funding:

Funding was raised by the researchers

Target disease:

gynecological cancer

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

研究虚弱对接受妇科肿瘤根治术患者术后恢复质量(疼痛、身体舒适度、身体活动度、心理支持和情绪状态)的影响。  

Objectives of Study:

To study the effect of frailty on postoperative recovery quality (pain , physical comfort , physical independence, psychological support and emotional state) of patients undergoing radical surgery for gynecological tumors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

诊断为妇科恶性肿瘤(卵巢、宫颈、子宫内膜或外阴)并且全麻下拟行妇科肿瘤根治术的患者。

Inclusion criteria

Patients were diagnosed as a gynecological cancer (ovary, cervix, endometrium or vulva) and planned to undergo radical resection of gynecological tumor under general anesthesia.

排除标准:

1.对阿片类药物过敏者,有药物滥用或酗酒史者;
2.正在服用镇静剂或抗抑郁药等精神病患者;
3.有严重器质性病变者(心、肺、肝、肾等器官);
4.腹水>2000ml或血红蛋白<60g/L或白蛋白<30g/L的患者;
5.术前接受放疗或化疗患者或者二次手术患者;
6.术前接受胃肠内营养的患者;
7.有认知功能障碍,听觉障碍,精神及神经类疾病。

Exclusion criteria:

1.Allergy to iodine, alcohol or drug abuse.
2.Psychiatric patients who are taking sedatives and antidepressants;
3. disease or injury affecting the central nervous system;
4.ascites >2000ml or hemoglobin <60g/L or albumin<30g/L;
5.preoperative radiotherapy and chemotherapy or secondary operation;
6.preoperative gastroenteral nutrition.

研究实施时间:

Study execute time:

From 2021-06-10 00:00:00 To 2022-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-06-10 00:00:00 To 2022-10-31 00:00:00  

干预措施:

Interventions:

组别:

虚弱组

样本量:

100

Group:

Weak group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

非虚弱组

样本量:

100

Group:

Non-weak group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

合肥 

Country:

China 

Province:

Anhui 

City:

Hefei 

单位(医院):

中国科学技术大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

虚弱

指标类型:

主要指标

Outcome:

frailty

Type:

Primary indicator

测量时间点:

术前

测量方法:

Measure time point of outcome:

preoperative

Measure method:

指标中文名:

恢复质量15项

指标类型:

主要指标

Outcome:

the Quality of Recovery 15 score (QoR-15)

Type:

Primary indicator

测量时间点:

术前和术后

测量方法:

Measure time point of outcome:

preoperative and postoperative

Measure method:

指标中文名:

并发症

指标类型:

主要指标

Outcome:

complication

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

主要指标

Outcome:

hospital stays

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

30天死亡率

指标类型:

主要指标

Outcome:

30-day death rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

二次手术率

指标类型:

主要指标

Outcome:

second operation rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由不参与研究的护士根据虚弱量表将病人分为虚弱组和非虚弱组。

Randomization Procedure (please state who generates the random number sequence and by what method):

A research nurse who don't involved in the study divided the patients into the frailty group and the non-frailty group according to the frailty scale.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan 临床试验公共管理平台, http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-06-08 01:36:37